Sundaram G. Veerappan

Sundaram G. Veerappan

Auto-generated profile, based on publicly available information

Sundaram G. Veerappan

Department of Gastroenterology, Adelaide and Meath Hospital, Tallaght, Dublin, Republic of Ireland

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2011 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
SVS. G. Veerappan
S. G. Veerappan
COC. A. O’morain
C. A. O’morain
JDJ. S. Daly
J. S. Daly
BRB. M. Ryan
B. M. Ryan

1 November 2016 in European Journal of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
SVSundaram G. Veerappan
Sundaram G. Veerappan
MHMartin Healy
Martin Healy
BWBernard Walsh
Bernard Walsh
COColm A. O’morain
Colm A. O’morain
JDJacqueline S. Daly
Jacqueline S. Daly
BRBarbara M. Ryan
Barbara M. Ryan
IFX treatment induced beneficial effects on bone metabolism. Osteoblast culture results suggest that IBD patients may have increased osteoblast viability, but reduced differentiation, which has implications for bone strength.

1 June 2008 in European Journal of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
SVSundaram G. Veerappan
Sundaram G. Veerappan
MKMary Kennedy
Mary Kennedy
COColm A. Oʼmorain
Colm A. Oʼmorain
BRBarbara M. Ryan
Barbara M. Ryan

1 July 2009 in European Journal of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
SVSundaram G. Veerappan
Sundaram G. Veerappan
COColm A. Oʼmorain
Colm A. Oʼmorain
Here we describe a patient with ulcerative colitis who developed alveolitis after infliximab therapy. With earlier case reports of development of alveolitis in rheumatoid arthritis patients after infliximab infusion, the temporal relationship between the infliximab therapy and the development of alveolitis in this case, raises the possibility that the two might be causally related. With an increasing trend towards treating moderate to severely active ulcerative colitis patients with infliximab as a rescue therapy, clinicians should be aware of this potentially serious complication.

24 October 2008 in Irish Journal of Medical Science (1971 -)
Verified
Journal Article
Closed access
PDF file
SVS. G. Veerappan
S. G. Veerappan
GMG. Moinuddin
G. Moinuddin
MKM. Kennedy
M. Kennedy
COC. A. O’morain
C. A. O’morain
DKD. Kane
D. Kane

1 December 2007 in Expert Review of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
SVSundaram G Veerappan
Sundaram G Veerappan
COColm A O’morain
Colm A O’morain